top of page

Browse by category

Search

SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs

SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs

SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs

Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...

Anti-obesity medications remain prohibitively expensive

Anti-obesity medications remain prohibitively expensive

Anti-obesity medications remain prohibitively expensive

Several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to...

SURPASS-4 trial: Tirzepatide slows rate of eGFR decline and reduces UACR in T2DM patients

SURPASS-4 trial: Tirzepatide slows rate of eGFR decline and reduces UACR in T2DM patients

SURPASS-4 trial: Tirzepatide slows rate of eGFR decline and reduces UACR in T2DM patients

An analysis of the SURPASS-4 trial has reported that type 2 diabetics with high cardiovascular risk who took resulted in a slowed the...

Framework focuses on the effects of excess adiposity on organs and tissues

Jul 31

First US patient treated with Proximal Intestinal Mucosal Ablation for the treatment of T2DM

Jul 28

Medtronic unveils Touch Surgery Aide - the next-generation compute platform for the OR

Jul 23

Back to Top

bottom of page